Thermo Fisher Scientific expects significant growth in its Indian customer base and revenue over the next five years, driven by the expanding biopharmaceutical sector. This positive outlook is supported by strategic regional investments and plans for workforce expansion, indicating a strong commitment to a high-growth market.
Thermo Fisher Scientific (TMO) is projecting 15-20% customer base growth in India over the next five years, fueled by the country's burgeoning biopharmaceutical, clean energy, and semiconductor industries. This is a significant positive development for TMO, as India is already one of its fastest-growing markets and contributes substantially to its Asia-Pacific revenue (18% of global revenue). The company plans increased regional investments and workforce expansion, particularly in customer-facing roles, to capitalize on this growth. This indicates a long-term strategic focus on a high-potential market, which could lead to sustained revenue growth and improved profitability for TMO, especially given its recent earnings beat. For traders, this highlights a key growth driver for TMO, suggesting potential for continued upward momentum.